• 42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)

  • Nov 23 2024
  • Length: 37 mins
  • Podcast

42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)

Listen for free

View show details

  • Summary

  • Discussão do artigo: "Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)" de Borchmann P Lancet 2024

    Apresentado por: Dr. Gabriel Coquito

    Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about 42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available